

Medical Therapies Ltd (ASX:MTY)

Looking to profit from large IP portfolio...

Important European patent granted. The IP Portfolio has grown with the addition of a European patent for treatment of narrowing of blood vessels. It adds another patent with the possibility to enter into lucrative licensing deals.

Independent research shows midkine can enhance breast cancer diagnostic. Independent research at Kumamoto University has shown that midkine, when used in tandem with traditional markers, can increase cancer detection from 29.9% to 44.9%. This helps validating the company's cancer diagnostic technology and could increase the value of licensing deals.

MTY is currently in negotiations with a number of potential licensees for its cancer diagnostic portfolio. A number of discussions are on foot between biopharmaceutical companies and Medical Therapies with the possibility to sign licensing deals in relation to the company's cancer diagnostic assets. Typically, diagnostic licenses include an upfront payment, funding for product development and in some cases milestone and royalty payments. MTY currently holds 4 diagnostic patent families and more than 20 granted patents around midkine with multiple opportunities for license deals.

Agreement signed with Kumamoto University. The University will further validate midkine as a diagnostic and therapeutic agent. MTY has supplied its antibodies to their research team and in return receive first rights to commercialise any new discoveries. Apart from the obvious saving of R&D expenditure, MTY gains independent verification of its diagnostic technology.

Appointment of ex Arana Chairman to the Board. Mr Robin Beaumont, who was Chairman of Arana, one of the largest Australian biotech companies, has been appointed to the Board of Medical Therapies. His appointment is a strong endorsement of Medical Therapies both in terms of its technology and business potential.

Recent \$550,000 capital raising complete at 2.2c. This puts the current cash balance at over \$200,000. The monies raised have been used for product development, patent support and for working capital. The company is looking at funding its product development expenditure with a mixture of some equity capital raising and licensing revenues.

18-10-2009

SPEC BUY

Analyst: Sven Restel
svenr@wise-owl.com

Website: www.medicaltherapies.com.au

Board of Directors

Chairman	Dr David King
Managing Director	Maria Halasz
Director	Koichiro Koike
Director	Robin Beaumont


Major Shareholders

Cell Signals	18.9%
Top 20 holders	65%

Share Data

Sector	Biotech
Market Cap	\$6.15m
Share price	\$0.029
Shares on issue	212m
Options on issue	
Avg. Daily Value	
Traded (30 days)	\$6,110

Medical Therapies Ltd 12 month chart



MTY AU: Medical Therapies Ltd G-1 Daily 5/15/08 to 5/11/09 Copyright © 2009 Bloomberg Finance L.P. 15-May-2009 10:01:45

Source: Bloomberg